Intraperitoneal carboplatin with or without interferon-α in advanced ovarian cancer patients with minimal residual disease at second look: A prospective randomized trial of 111 patients

Gynecologic Oncology

Volumn 65, Issue 3, 1997, Pages 499-505

  Bruzzone, M ^a   Rubagotti, A ^a   Gadducci, A ^a   Catsafados, E ^a   Foglia, G ^a   Brunetti, I ^a   Giannessi, P G ^a   Carnino, F ^a   Iskra, L ^a   Rosso, R ^a   Martoni, A ^a   Pannuti, F ^a   De Lisi, V ^a   Maltoni, R ^a   Ridolfi, R ^a   Mammoliti, S ^a   Gallo, L ^a   Boccardo, F ^a   Ragni, N ^a   Conte, P F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CARBOPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 17644446519     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4689     Document Type: Article

References (38)

1. 1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303:884-893, 1991
2. 2. Vermorken JB: Consolidation therapy in patients with advanced ovarian cancer. Eur J Gynaecol Oncol 15(1):7-13, 1994
3. 3. Willemse PHB, Sleijfer DTh, De Vries EGE, Boonstra H, Bouma J, Mulder NH: A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer. Eur J Cancer 28(23):479-481, 1992
4. 4. Menczer J, Ben-Baruch G, Rizel S, Brenner H: Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission. Cancer 70(7): 1956-1959, 1992
5. 5. De Gramont A, Demuynck B, Louvet C, Gonzales-Canali G, Varette C, Pignè A, Marpeau L, Herbulot P, Lagadec B, Cady J, Soubrane D, Couturier JY, Delfau S, Sezeur A, Gallot D, Malafosse M, Barrat J, Krulik M: Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. Am J Clin Oncol 15(1):7-11, 1992
6. 6. Bruzzone M, Repetto L, Chiara S, Campora E, Conte PF, Orsatti M, Vitale V, Rubagotti A, Rosso R: Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 38:392-395, 1990
7. 7. Dufour P, Bergerat JP, Liu KL, Bohbot A, Maloisel F, Duclos B, Herbrechtt R, Faradji A, Jung JM, Oberling F: High dose melphalan and ABMT with or without abdominal radiotherapy as consolidation treatment for ovarian carcinoma in complete remission or with microscopic residual disease. Eur J Gynaecol Oncol 12(6):457-461, 1991
8. 8. Menczer J, Ben-Baruch G, Modan M, Brenne H: Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Cancer 63:1509-1513, 1989
9. 9. Beller U, Speyer J, Colombo N, Sorich J, Wernz H, Hochster A, Zeleniuch-Jacquotte A, Porges R, Beckman EM: Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. J Clin Oncol 9(5):809-817, 1991
10. 10. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD: Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant α-interferon. Gynecol Oncol 45:3-8, 1992
11. 11. Piccart MJ, Abrams J, Dodion PF, Crespeigne N, Sculier JP, Pector JC, Finet C, Nouwijnck C, Bondue H, Atassi G, Kenis Y: Intraperitoneal chemotherapy with cisplatin and melphalan. J Natl Cancer Inst 80:1118-1124, 1988
12. 12. Brenner DE: Intraperitoneal chemotherapy: a review. J Clin Oncol 4(7): 1135-1147, 1986
13. 13. Markman M: Intraperitoneal chemotherapy. Semin Oncol 18(3):248-254, 1991
14. 14. Berek JS: Intraperitoneal immunotherapy for ovarian cancer with a-Interferon. Eur J Cancer 28A(4/5):719-721, 1992
15. 15. Frasci G, Tortoriello A, Facchini G, Conforti S, Cardone A, Persico G, Mastrantonio P, Iaffaioli RV: Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-α2b in ovarian cancer patients with minimal residual disease. Gynecol Oncol 50:60-67, 1993
16. 16. Ferrari E, Maffeo DA, Graziano R, Gallo MS, Pignat S, Derosa L, Montella M, Pergola M: Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. Eur J Gynaecol Oncol 15(6):437-442, 1994
17. 17. Willemse PHB, de Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DTH: Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Clin Oncol 26:353-358, 1990
18. 18. Berek JS, Welander C, Schinkm JC, Grossberg H, Montz FJ, Zigelboim J: A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with residual epithelial ovarian cancer. Gynecol Oncol 40:237-243, 1991
19. 19. Itri LM: The interferons. Cancer 70:940-945, 1992
20. 20. Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G: Intraperitoneal recombinant alpha-2 interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer: a phase II study. J Clin Oncol 8:1036-1041, 1990
21. 21. Welander C, Morgan TM, Homesley H, Trotta PP, Spigel RJ: Combined recombinant human interferon-a and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35:721-729, 1987
22. 22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. 23. Meinert CL: Clinical Trials: Design, Conduct and Analysis. London: Oxford Univ. Press, 1986
24. 24. Kaplan ER, Meiner P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
25. 25. Lee ET: Statistical Methods for Survival Data Analysis. Belmont CA: Like Time Learning Publications (1980)
26. 26. Dauplat J, Legros M, Condat P, Ferriere JP, Ben Ahmed S, Plagne R: High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 34:294-298, 1989
27. 27. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE: A randomized trial comparising single-agent carboplatin with folowed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 11:440, 1993
28. 28. Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W: Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10(9): 1479-1484, 1992
29. 29. Bolis G, Crippa F, Gavoni N, Marini A, Presti M, Buraggi GL: Intraperitoneal radioimmunotherapy with MOV 18 in minimal residual disease advanced ovarian cancer. Ann Oncol 3(Suppl 5): 101, 1992 [abstract 338]
30. 30. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JL, Barakat R, Rubin S, Mychalczak B, Saigo P, Almadrones L, Hoskins W: Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 71:1565-1570, 1993
31. 31. Alberts DS: Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22(5) (Suppl 12):88-90, 1995
32. 32. Markmann M: Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. Semin Oncol 21(2) (Suppl 2): 17-19, 1994
33. 33. Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, Gree M, Porges R, Muggia FM, Canetta R, Beckman EM: Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 8(8): 1335-1341, 1990
34. 34. Bookman MA, Bast RC Jr: The immunobiology and immunotherapy of ovarian cancer. Semin Oncol 18(3):270-291, 1991
35. 35. Pujade-Lauraine E, Colombo N, Namer N, Fumoleau P, Monnier A, Nooy MA, Falkson G, Mignot L, Bugat R, Oliveira CMD, Mousseau M, Netter G, Oberling F, Coiffier B, Brandely M: Intraperitoneal human r-IFN gamma in patients with residual ovarian carcinoma at second look laparotomy. Proc ASCO 9:156, 1990 [abstract 603]
36. 36. Welander ChE: Interferon in the treatment of ovarian cancer. Semin Oncol 15(5) (Suppl 5):26-29, 1988
37. 37. Nicoletto MO, Fiorentino MV, Vinante O, Prosper A, Tredese F, Tumolo S, Cima GP, Monfardini S: Experience with intraperitoneal alpha-2a interferon. Oncology 49:467-473, 1992
38. 38. Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R: Intraperitoneal chemotherapy with carboplatin and interferon-alpha in the treatment of relapsed ovarian cancer: a pilot study. Anticancer Res 11:1641-1643, 1991